^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | nintedanib (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
11/21/2014
Excerpt:
Vargatef is indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first line chemotherapy.
Secondary therapy:
docetaxel
